Reducing the burden of bilateral injections
07/21/23 • 20 min
We are delighted to announce that we are expanding A Chat with Anat! We will be partnering with the Vision Academy, a group of retinal experts who collaborate to provide guidance to the retinal community. I will be joined by internationally renowned Vision Academy experts to discuss practice-focused topics covering clinical challenges in ophthalmology and controversies in care.
In this episode of A Chat with Anat, Professor Paul Mitchell, Professor of Ophthalmology at the University of Sydney, and Dr Alex Hunyor, Associate Professor of Ophthalmology at the University of Sydney, discuss pragmatic considerations to reduce the burden of bilateral anti-VEGF injections.
Professor Mitchell and Dr Hunyor explore how bilateral disease significantly impacts patient quality of life, and how bilateral treatment, especially if the eyes are being treated on different days, can lead to significant burden for patients, caregivers, and for their healthcare system.
Their conversation also covers how to explain to patients the need for, and risks of, bilateral injections, and how we, as ophthalmologists, can minimise any potential risks with the treatment procedure.
The Vision Academy viewpoint providing guidance on bilateral injections, and other important viewpoints and resources, can be found at https://www.visionacademy.org/. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.
If you enjoyed this episode, please listen to past episodes in this series to hear retinal experts discussing their experiences in navigating the importance of addressing anxiety and depression in our patients with nAMD, and how patients’ emotions, experiences, and perceptions can influence their treatment adherence and persistence.
SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!
Further information on content in other podcasts in this series can be found at: https://www.amdbarometer.org/resources
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
July 2023 MA-PFM-OPHT-ALL-1181-1
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
We are delighted to announce that we are expanding A Chat with Anat! We will be partnering with the Vision Academy, a group of retinal experts who collaborate to provide guidance to the retinal community. I will be joined by internationally renowned Vision Academy experts to discuss practice-focused topics covering clinical challenges in ophthalmology and controversies in care.
In this episode of A Chat with Anat, Professor Paul Mitchell, Professor of Ophthalmology at the University of Sydney, and Dr Alex Hunyor, Associate Professor of Ophthalmology at the University of Sydney, discuss pragmatic considerations to reduce the burden of bilateral anti-VEGF injections.
Professor Mitchell and Dr Hunyor explore how bilateral disease significantly impacts patient quality of life, and how bilateral treatment, especially if the eyes are being treated on different days, can lead to significant burden for patients, caregivers, and for their healthcare system.
Their conversation also covers how to explain to patients the need for, and risks of, bilateral injections, and how we, as ophthalmologists, can minimise any potential risks with the treatment procedure.
The Vision Academy viewpoint providing guidance on bilateral injections, and other important viewpoints and resources, can be found at https://www.visionacademy.org/. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.
If you enjoyed this episode, please listen to past episodes in this series to hear retinal experts discussing their experiences in navigating the importance of addressing anxiety and depression in our patients with nAMD, and how patients’ emotions, experiences, and perceptions can influence their treatment adherence and persistence.
SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!
Further information on content in other podcasts in this series can be found at: https://www.amdbarometer.org/resources
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
July 2023 MA-PFM-OPHT-ALL-1181-1
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
Previous Episode
Navigating anxiety and depression in patients with nAMD
My guest for this episode is Professor Tariq Aslam, Professor of Ophthalmology and Interface Technologies at the University of Manchester and a Consultant Ophthalmologist specializing in the management of retinal disease. In this episode, we speak about how important it is to consider anxiety and depression when managing our patients with nAMD, and hear about the quick and effective measures that listeners can implement in their own clinic to identify patients at risk of anxiety and depression.
Visit the resources page of the Barometer website to learn more about the rapid mental health screening tool that can be used to identify and support patients at risk of anxiety and depression https://www.amdbarometer.org/resources. For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites, and visit the Vision Academy website for information on managing clinically challenging situations and controversies in care.
If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode!
Speaker disclosures:
Professor Anat Loewenstein - Consultancy, Research grants: Allergan, Bayer, Beyeonics Surgical, KHB, Novartis, Notal Vision, Oculis, Oxurion, Pres-By, Roche, Sensor, WebMD, Xbrane. Professor Tariq Aslam - Consultancy: Bausch & Lomb, Bayer, Laboratoires, Novartis, Oraya, Théa Pharmaceuticals.
Further information on other studies mentioned in this episode:
Senra H, Balaskas K, Mahmoodi N, Aslam T. Experience of Anti-VEGF Treatment and Clinical Levels of Depression and Anxiety in Patients With Wet Age-Related Macular Degeneration. Am J Ophthalmol. 2017;177:213─224.
Cimarolli VR, Casten RJ, Rovner BW, Heyl V, Sörensen S, Horowitz A. Anxiety and depression in patients with advanced macular degeneration: current perspectives. Clin Ophthalmol. 2015;10:55─63.
Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939─46.
Weinstein O, Cohen AD, Levy J, Zloto O, Freud T, Krieger I, Comaneshter D, Shemesh R. Anxiety in Patients with Neovascular Age-related Macular Degeneration. Ophthalmic Epidemiol. 2023;30:286─292.
January 2025 - MA-PFM-OPHT-ALL-1086-1
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
Next Episode
Optimal anti-VEGF therapy regimen
In this episode, Professor Paul Mitchell, Professor of Ophthalmology at the University of Sydney in Australia, and Dr Andrew Chang, Principal Retinal Specialist at the Sydney Retina Clinic and Day Surgery in Australia, share their thoughts on the optimal anti-VEGF therapy regimens to treat retinal vascular diseases, including nAMD and DME. They discuss how the best regimen should be effective in maintaining vision, proactive, individualized to the patient’s needs, and convenient for the patient.
Using practical examples from their own clinics, Professor Mitchell and Dr Chang explore how to treat different patients with different levels of starting visual acuity, and how treatments for retinal vascular diseases have changed over time.
This podcast is produced in partnership with the Vision Academy, a group of internationally renowned retinal experts who collaborate to provide guidance to the retinal community on clinical challenges in ophthalmology and controversies in care.
The Vision Academy viewpoints providing guidance on clinically challenging situations, and other important resources, can be found at https://www.visionacademy.org/. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before subscribing.
If you enjoyed this episode, please listen to past episodes in this series to hear retinal experts discussing their thoughts on bilateral retinal disease and treatment, how to optimize treatment of patients with nAMD with macular neovascularization subtypes, and how patients’ emotions, experiences, and perceptions can influence their treatment adherence and persistence.
SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!
Further information on other studies mentioned in this episode:
ARIES study: Mitchell et al., Efficacy and Safety of Intravitreal Aflibercept Using a Treat-and-Extend Regimen for Neovascular Age-Related Macular Degeneration. The ARIES Study: A Randomized Clinical Trial https://journals.lww.com/retinajournal/Fulltext/2021/09000/EFFICACY_AND_SAFETY_OF_INTRAVITREAL_AFLIBERCEPT.15.aspx
July 2023 MA-PFM-OPHT-ALL-1183-1
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/a-chat-with-anat-473558/reducing-the-burden-of-bilateral-injections-63675528"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to reducing the burden of bilateral injections on goodpods" style="width: 225px" /> </a>
Copy